A Bayesian approach for dose-escalation in a phase I clinical trial incorporating pharmacodynamic endpoints

Journal of Biopharmaceutical Statistics

Volumn 17, Issue 6, 2007, Pages 1117-1129

  Whitehead, John ^a   Zhou, Yinghui ^b   Hampson, Lisa ^c   Ledent, Edouard ^d,e   Pereira, Alvaro ^d,f  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

^c University of Bath   (United Kingdom)

^d ELI LILLY AND COMPANY   (United States)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^f Aepodia SA   (Belgium)

Author keywords

Bayesian procedure; Dose escalation; Pharmacodynamic responses; Phase I clinical trial

Indexed keywords

ATOMOXETINE; NORADRENALIN; PLACEBO;

ADRENERGIC SYSTEM; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; BAYES THEOREM; BLOOD PRESSURE; CHOLINERGIC SYSTEM; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG MECHANISM; HEART RATE; HEART RHYTHM; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MOTIVATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN TRANSPORT; UNSPECIFIED SIDE EFFECT;

BAYES THEOREM; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; HUMANS; LIKELIHOOD FUNCTIONS;

EID: 36249027131     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400701645165     Document Type: Conference Paper

References (14)

1. Chevret, S. Ed. (2006). Statistical Methods for Dose-Finding Experiments. Chichester: Wiley.
2. O'Quigley, J., Pepe, M., Fisher, L. (1990). Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46:33-48.
3. Piantadosi, S., Liu, G. (1996). Improved designs for dose escalation studies using pharmacokinetic measurements. Statistics in Medicine 15:1605-1618.
4. Rosenberger, W. F., Haines, L. M. (2002). Competing designs for phase I clinical trials: a review. Statistics in Medicine 21:2757-2770.
5. Ting, N. Ed. (2006). Dose Finding in Drug Development. New York: Springer.
6. Tsutakawa, R. K. (1975). Bayesian inference for bioassay. Technical Report 52, Mathematical Sciences, University of Missouri, Columbia.
7. Wernicke, J. F., Faries, D., Girod, D., Brown, J. W., Gao, H., Kelsey, D., Quintana, H., Lipetz, R., Michelson, D., Heiligenstein, J. (2003). Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Safety 26:729-740.
8. Whitehead, J., Williamson, D. (1998). An evaluation of Bayesian decision procedures for dose-finding studies. Journal of Biopharmaceutical Statistics 8:445-467.
9. Whitehead, J., Zhou, Y., Mander, A., Ritchie, S., Sabin, A., Wright, A. (2006a). An evaluation of Bayesian designs for dose-escalation studies in healthy volunteers. Statistics in Medicine 25:433-445.
10. Whitehead, J., Zhou, Y., Patterson, S., Webber, D., Francis, S. (2001). Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. Biostatistics 2:47-61.
11. Whitehead, J., Zhou, Y., Stevens, J., Blakey, G., Price, J., Leadbetter, J. (2006b). Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit. Statistics in Medicine 25:37-53.
12. Zhou, Y., Whitehead, J. (2003). Practical implementation of Bayesian dose-escalation procedures. Drug Information Journal 37:45-59.
13. Zhou, Y., Whitehead, J., Bonvini, E., Stevens, J. (2006). Bayesian decision procedures for binary and continuous bivariate dose-escalation studies. Pharmaceutical Statistics 5:125-133.
14. Zhou, Y., Whitehead, J., Korhonen, P., Mustonen, M. (2007). Implementation of a Bayesian design in a dose-escalation study of an experimental agent in healthy volunteers. Biometrics. In press.